Federal Contractor Profile
Lovelace Biomedical Research Institute
$137M obligated·169 awards·6 agencies·14 NAICS
Federal Contracts
Showing award actions 51–100 of 209 funded award actions, most recent first.
- Contracts with positive obligations
- 169
- Funded award actions shown
- 209
- Obligations shown
- $137M
- Awarding agencies
- 6
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of November 5, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Apr 5, 2023 | Department of DefenseFA9451 AFRL RDK | FA945120P0019 | 541380 | COVID-19 THE PURPOSE OF VIDER IS TO UNDERSTAND THE EFFECTIVENESS OF RF DIRECTED ENERGY RADIATION IN REDUCING THE VIABILITY OF VIRAL AEROSOLS WITH THE GOAL OF RAPIDLY DEVELOPING AND DEPLOYING REMEDIATION METHODS FOR SPACES CONTAMINATED WITH SARS-COV-2 | $13K |
| Mar 31, 2023 | Department of DefenseFA9451 AFRL RDK | FA945120P0019 | 541380 | COVID-19 THE PURPOSE OF VIDER IS TO UNDERSTAND THE EFFECTIVENESS OF RF DIRECTED ENERGY RADIATION IN REDUCING THE VIABILITY OF VIRAL AEROSOLS WITH THE GOAL OF RAPIDLY DEVELOPING AND DEPLOYING REMEDIATION METHODS FOR SPACES CONTAMINATED WITH SARS-COV-2 | $10K |
| Dec 16, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92019F00074 | 541714 | THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES. | $48K |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122D00021 | 541714 | LOVELACE BIOMEDICAL RESEARCH INSTITUTE - BASE (BIO) - IDIQ FOR BARDA BIOLOGICAL ANIMAL MODEL AND MCM DEVELOPMENT | $75K |
| Sep 28, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541715 | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | $440K |
| Sep 26, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541714 | GLP REPEAT DOSE TOXICOLOGY STUDY FOR BPL-24910 | $716K |
| Sep 23, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $798K |
| Sep 23, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $500K |
| Sep 22, 2022 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40122F19001 | 541690 | CTP-2022-111127 - SALTS | $2.1M |
| Sep 20, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541715 | ASSESSMENT OF POTENTIAL TREATMENTS FOR DRUG-INDUCED RESPIRATORY DEPRESSION AND OVERDOSE TOXICITY. POP: SEPTEMBER 26, 2022 - MARCH 25, 2023. TASK ORDER 75N95022F00001 (TO1). | $149K |
| Sep 20, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00002 | 541715 | ASSESSMENT OF POTENTIAL TREATMENTS FOR DRUG-INDUCED RESPIRATORY DEPRESSION AND OVERDOSE TOXICITY. POP: SEPTEMBER 26, 2022 - MARCH 25, 2023. TASK ORDER 75N95022F00002 (TO2). | $163K |
| Sep 20, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00003 | 541715 | ASSESSMENT OF POTENTIAL TREATMENTS FOR DRUG-INDUCED RESPIRATORY DEPRESSION AND OVERDOSE TOXICITY. POP: SEPTEMBER 26, 2022 - SEPTEMBER 25, 2023. TASK ORDER 75N95022F00003 (TO3). | $103K |
| Sep 16, 2022 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $212K |
| Sep 14, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92022F00250 | 561320 | NIH/NHBLI/PSB LAB RESEARCHER REQUIRES MOUSE STUDY OF SMOKING REQUIRED IN ORDER TO TO FOLLOW UP ON RESEARCH AIMS OF LEVY LAB AND CONTINUE DEVELOPING THERAPEUTIC TARGET. [22-018080] | $25K |
| Sep 9, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92022F00001 | 541714 | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY | $1.3M |
| Aug 31, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122D00013 | 541714 | LOVELACE BIOMEDICAL RESEARCH INSTITUTE (RADNUC) - IDIQ FOR BARDA CRN ANIMAL MODEL DEVELOPMENT | $75K |
| Aug 31, 2022 | Department of DefenseDEFENSE HEALTH AGENCY | HT001122F0101 | 541714 | MILITARY MEDICAL RESEARCH AND DEVELOPMENT SERVICES | $3K |
| Aug 3, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122F61001 | 541711 | SUPPORT NON-CLINICAL IMMUNOGENICITY STUDIES OF SARS-COV-2 MICRONEEDLE PATCH VACCINES CANDIDATES IN A SMALL-ANIMAL MODEL | $461K |
| Jul 27, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122D00008 | 541714 | LOVELACE BIOMEDICAL RESEARCH INSTITUTE(CHEM) - IDIQ FOR BARDA CRN ANIMAL MODEL DEVELOPMENT | $75K |
| Jul 22, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00088 | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $675K |
| Jun 23, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019D00030 | 541715 | CRO SUPPORT FOR NCATS MEDICINAL CHEMISTRY FOR LEAD OPTIMIZATION. | $4K |
| Jun 16, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541715 | BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS | $748K |
| Jun 13, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00005 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $172K |
| May 11, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $71K |
| Apr 6, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00088 | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $227K |
| Apr 6, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $370K |
| Mar 8, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122F61001 | 541711 | SUPPORT NON-CLINICAL IMMUNOGENICITY STUDIES OF SARS-COV-2 MICRONEEDLE PATCH VACCINES CANDIDATES IN A SMALL-ANIMAL MODEL | $295K |
| Dec 16, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92019F00074 | 541714 | THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES. | $60K |
| Dec 3, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00004 | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $180K |
| Nov 15, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00088 | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $255K |
| Nov 12, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541715 | THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA | $486K |
| Sep 28, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00002 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. | $624K |
| Sep 24, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00004 | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $282K |
| Sep 24, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $584K |
| Sep 8, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541715 | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | $63K |
| Sep 7, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00088 | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $595K |
| Sep 3, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92021F00001 | 541714 | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY - SCIENTIFIC PROJECT FOR RSA NO. 2057 (RADER) | $1.6M |
| Aug 31, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021F00001 | 541714 | COMPREHENSIVE AND RAPID RESPONSE FOR NIAID RESEARCH PROGRAMS | $2K |
| Aug 30, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $269K |
| Aug 27, 2021 | Department of DefenseFA8052 773 ESS | 0011 | 541712 | IGF::OT::IGF OMNIBUS III / O3-127AF PAIN MANAGEMENT PROGRAM MANAGEMENT SUPPORT | $270K |
| Aug 23, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH17C0235 | 511210 | IGF::OT::IGF ANIMAL MANAGEMENT SYSTEM SOFTWARE LICENSE/SUPPORT | $202K |
| Aug 19, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92020F00001 | 541714 | GENE THERAPY RESEARCH PROGRAM (GTRP) - PHARMACOLOGY/TOXICOLOGY CORE LABORATORY: TASK AREA D - RSA NO. 2041 | $71K |
| Jul 15, 2021 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | HHSF22301003T | 541720 | IGF::OT::IGF: INVESTIGATE SUBJECTIVE EFFECTS AND NICOTINE PHARMACOKINETICS OF MENTHOLATED SMOKELESS TOBACCO PRODUCTS IN CURRENT USERS | $22K |
| Jun 15, 2021 | Department of DefenseFA9451 AFRL RDK | FA945120P0019 | 541380 | COVID-19 THE PURPOSE OF VIDER IS TO UNDERSTAND THE EFFECTIVENESS OF RF DIRECTED ENERGY RADIATION IN REDUCING THE VIABILITY OF VIRAL AEROSOLS WITH THE GOAL OF RAPIDLY DEVELOPING AND DEPLOYING REMEDIATION METHODS FOR SPACES CONTAMINATED WITH SARS-COV-2 | $100K |
| Jun 1, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020F00001 | 541711 | PRE-CLINICAL MODELS OF INFECTIOUS DISEASES TASK ORDER B07 | $340K |
| May 25, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $224K |
| Apr 6, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021F00002 | 541715 | THE PURPOSE OF THIS TASK ORDER IS THE DEVELOPMENT AND DELIVERY OF A QUALITY ASSURANCE/QUALITY CONTROL (QA/QC) PLAN AND PARTICIPATION IN THE TASK ORDER INITIATION MEETING. | $19K |
| Mar 1, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00088 | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $415K |
| Jan 15, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00004 | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $102K |
| Dec 3, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92019F00074 | 541714 | THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES. | $397K |
Get Alerted Before Lovelace Biomedical Research Institute's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free